國家衛生研究院 NHRI:Item 3990099045/12150
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2478239      線上人數 : 54
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12150


    題名: Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice
    作者: Chiang, H;Lee, JC;Huang, HC;Huang, H;Liu, HK;Huang, C
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: BACKGROUND AND PURPOSE: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is closely related to metabolic diseases such as obesity and diabetes. Despite an accumulating number of studies, no pharmacotherapy that targets NAFLD has received general approval for clinical use. EXPERIMENTAL APPROACH: Sodium glucose cotransporter 2 (SGLT2) inhibition is a promising approach to treat diabetes, obesity, and associated metabolic disorders. In this study, we investigated the effect of a novel SGLT2 inhibitor, NGI001, on NAFLD and obesity-associated metabolic symptoms in high fat diet (HFD)-induced obese mice. KEY RESULTS: Delayed intervention with NGI001 protected against body weight gain, hyperglycemia, hyperlipidemia and hyperinsulinemia, compared with HFD alone. Adipocyte hypertrophy was prevented by administering NGI001. NGI001 inhibited impaired glucose metabolism and regulated the secretion of adipokines associated with insulin resistance. In addition, NGI001 supplementation suppressed hepatic lipid accumulation and inflammation, and had little impact on kidney function. In-depth investigations showed NGI001 ameliorated fat deposition and increased AMPK phosphorylation, resulting in phosphorylation of its major downstream target, ACC, in human hepatocytes, HuS-E/2 cells. This cascade ultimately led to the downregulation of downstream fatty acid synthesis-related molecules and the upregulation of downstream beta oxidation-associated molecules. Surprisingly, NGI001 decreased gene and protein expression of SGLT1 and SGLT2 and glucose uptake in oleic acid-treated HuS-E/2 cells. CONCLUSION AND IMPLICATIONS: Our findings suggest the therapeutic potential of the novel SGLT2 inhibitor, NGI001, to attenuate or delay the onset of diet-induced metabolic diseases and NAFLD.
    日期: 2020-01-01
    關聯: British Journal of Pharmacology. 2020 Jan 1;177(2):239-253.
    Link to: http://dx.doi.org/10.1111/bph.14859
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0007-1188&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000495923400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85074984198
    顯示於類別:[李靜琪] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB31497874.pdf9935KbAdobe PDF316檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋